## Edgar Filing: CORTEX PHARMACEUTICALS INC/DE/ - Form 4

	239	a. i migi	001112				0	0,02,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,				
CORTEX PH Form 4 July 21, 2014	IARMACEUTI	CALS IN	C/DE/									
FORM									OMB A	PPROVAL		
	UNTEL	<b>STATES</b>	S SECURITIES AND EXCHANGE C Washington, D.C. 20549					OMMISSION	OMB Number:	3235-0287		
if no long subject to Section 16 Form 4 or	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF								Expires: Estimated a burden hou response	irs per		
Form 5 obligation may conti <i>See</i> Instru 1(b).	$\frac{1}{1}$ Section 17	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, ction 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940										
(Print or Type R	esponses)											
1. Name and Address of Reporting Person <u>*</u> Lippa Arnold			2. Issuer Name <b>and</b> Ticker or Trading Symbol CORTEX PHARMACEUTICALS				S	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
		INC/DE	/ [CORX]				(Check an applicable)					
(Last) (First) (Middle) C/O CORTEX PHARMACEUTICALS, INC., 126 VALLEY ROAD, SUITE C			<ul><li>3. Date of Earliest Transaction</li><li>(Month/Day/Year)</li><li>07/17/2014</li></ul>					X DirectorX 10% Owner X Officer (give title Other (specify below) Chairman, CEO and President				
	(Street)	reet) 4. If Amendment, Date Original Filed(Month/Day/Year)						<ul> <li>6. Individual or Joint/Group Filing(Check Applicable Line)</li> <li>_X_ Form filed by One Reporting Person</li> <li> Form filed by More than One Reporting</li> </ul>				
GLEN ROC	K, NJ 07452							Person		epotung		
(City)	(State)	(Zip)	Table	e I - Non-Do	erivative S	ecurities	s Acq	uired, Disposed o	of, or Beneficia	lly Owned		
1.Title of Security (Instr. 3)	2. Transaction Da (Month/Day/Yea	r) Execution any		Transactio Code (Instr. 8)	onAcquired Disposed (Instr. 3, 4	(A) or of (D) 4 and 5) (A) or		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Common Stock				Code V	Amount	(D) P1	rice	15,000,000 <u>(1)</u>	I	By Arnold Lippa Family Trust of 2007 (1)		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control

## Edgar Filing: CORTEX PHARMACEUTICALS INC/DE/ - Form 4

## number.

## Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amour Underlying Securit (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amc Num Shar
Common Stock Options (to purchase shares of Common Stock)	\$ 0.05	07/17/2014		A	5,000,000	<u>(2)</u>	07/17/2019	Common Stock	5,0
Series G 1.5% Convertible Preferred Stock	(3)					<u>(3)</u>			